Lineage Cell Therapeutics
LCTX
LCTX
126 hedge funds and large institutions have $53.8M invested in Lineage Cell Therapeutics in 2024 Q4 according to their latest regulatory filings, with 28 funds opening new positions, 38 increasing their positions, 16 reducing their positions, and 13 closing their positions.
New
Increased
Maintained
Reduced
Closed
more repeat investments, than reductions
Existing positions increased: | Existing positions reduced:
more first-time investments, than exits
New positions opened: | Existing positions closed:
more funds holding
Funds holding: →
less ownership
Funds ownership: →
33% less funds holding in top 10
Funds holding in top 10: 3 → 2 (-1)
37% less capital invested
Capital invested by funds: $85.6M → $53.8M (-$31.8M)
Holders
126
Holding in Top 10
2
Calls
$37K
Puts
–
Top Buyers
| 1 | +$3.64M | |
| 2 | +$1.98M | |
| 3 | +$1.05M | |
| 4 |
DCM
DAFNA Capital Management
Los Angeles,
California
|
+$583K |
| 5 |
Jacobs Levy Equity Management
Florham Park,
New Jersey
|
+$519K |
Top Sellers
| 1 | -$4.53M | |
| 2 | -$670K | |
| 3 | -$511K | |
| 4 |
LFCM
Long Focus Capital Management
San Juan,
Puerto Rico
|
-$195K |
| 5 |
BCM
Bridgeway Capital Management
Houston,
Texas
|
-$170K |